DNA polymerase β as a novel target for chemotherapeutic intervention of colorectal cancer

PLoS ONE

Volumn 6, Issue 2, 2011, Pages

  Jaiswal, Aruna S ^a   Banerjee, Sanjeev ^b   Aneja, Ritu ^c   Sarkar, Fazlul H ^b   Ostrov, David A ^a   Narayan, Satya ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c GEORGIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 AMINO 6 IODO 2 OXO 5,6 DIHYDROPYRIMIDIN 1 YL) 3 HYDROXY OXOLAN 2 YL; ANTINEOPLASTIC AGENT; APC PROTEIN; DNA (APURINIC OR APYRIMIDINIC SITE) LYASE; DNA DIRECTED DNA POLYMERASE BETA; DNA LIGASE I; FLAP ENDONUCLEASE; FLAP ENDONUCLEASE 1; NSC 124854; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; DACARBAZINE; DRUG DERIVATIVE; ORGANOPHOSPHATE; PYRIMIDINONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; COLORECTAL CANCER; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG TARGETING; ENZYME ACTIVITY; EXCISION REPAIR; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR DOCKING; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; CARCINOMA; CELL STRAIN CACO 2; CELL STRAIN HCT116; CELL STRAIN HT29; COLORECTAL TUMOR; DRUG ANTAGONISM; GENETICS; METHODOLOGY; MOLECULARLY TARGETED THERAPY; MOUSE MUTANT; PATHOLOGY; PHYSIOLOGY; TUMOR CELL CULTURE; TUMOR CELL LINE;

MUS;

ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CACO-2 CELLS; CARCINOMA; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DACARBAZINE; DNA POLYMERASE BETA; DRUG SYNERGISM; FEMALE; HCT116 CELLS; HT29 CELLS; HUMANS; MICE; MICE, SCID; MOLECULAR TARGETED THERAPY; PHOSPHORIC ACID ESTERS; PYRIMIDINONES; TUMOR CELLS, CULTURED; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 79551652711     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0016691     Document Type: Article

References (69)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Abbas A, Yang G, Fakih M (2010) Management of anal cancer in 2010. Part 2: current treatment standards and future directions. Oncology (Williston Park) 24: 417-424.
3. Thompson PA, Gerner EW (2009) Current concepts in colorectal cancer prevention. Expert Rev Gastroenterol Hepatol 3: 369-382.
4. Miyoshi Y, Nagase H, Ando H, Horii A, Ichii S, et al. (1992) Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet 1: 229-233.
5. Powell SM, Zilz N, Beazer-Barclay Y, Bryan TM, Hamilton SR, et al. (1992) APC mutations occur early during colorectal tumorigenesis. Nature 359: 235-237.
6. Fodde R, Kuipers J, Rosenberg C, Smits R, Kielman M, et al. (2001) Mutations in the APC tumor suppressor gene cause chromosomal instability. Nat Cell Biol 3: 433-438.
7. Goss KH, Groden J (2000) Biology of the adenomatous polyposis coli tumor suppressor. J Clin Oncol 18: 1967-1979.
8. Fearnhead NS, Britton MP, Bodmer WF (2001) The ABC of APC. Hum Mol Genet 10: 721-733.
9. Narayan S, Roy D (2003) Role of APC and DNA mismatch repair genes in the development of colorectal cancers. Mol Cancer 2: 41.
10. Ishidate T, Matsumine A, Toyoshima K, Akiyama T (2000) The APC-hDLG complex negatively regulates cell cycle progression from the Go/G1 to S phase. Oncogene 19: 365-372.
11. Kaplan KB, Burds AA, Swedlow JR, Bekir SS, Sorger PK, et al. (2001) A role for the Adenomatous Polyposis Coli protein in chromosome segregation. Nat Cell Biol 3: 429-432.
12. Green RA, Wollman R, Kaplan KB (2005) APC and EB1 function together in mitosis to regulate spindle dynamics and chromosome alignment. Mol Biol Cell 16: 4609-4622.
13. Barth AIM, Pollack AL, Altschuler Y, Mostov KE, Nelson WJ (1997) NH2- terminal deletion of b-catenin results in stable colocalization of mutant b-catenin with adenomatpous polyposis coli protein and altered MDCK cell adhesion. J Cell Biol 136: 693-706.
14. Jaiswal AS, Narayan S (2008) A novel function of adenomatous polyposis coli (APC) in regulating DNA repair. Cancer Lett 271: 272-280.
15. Kouzmenko AP, Takeyama K, Kawasaki Y, Akiyama T, Kato S (2008) Truncation mutations abolish chromatin-associated activities of adenomatous polyposis coli. Oncogene 27: 4888-4899.
16. Deka J, Herter P, Sprenger-Haussels M, Koosch S, Franz D, et al. (1999) The APC protein binds to A/T rich DNA sequence. Oncogene 18: 5654-5661.
17. Qian J, Sarnaik A, Bonney T, Keirsey J, Combs K, et al. (2008) The APC tumor suppressor inhibits DNA replication by directly binding to DNA via its carboxyl terminus. Gastroenterology 135: 152-162.
18. Panda H, Jaiswal AS, Corsino PE, Armas ML, Law BK, et al. (2009) Amino acid Asp181 of 59-flap endonuclease 1 is a useful target for chemotherapeutic development. Biochemistry 48: 9952-9958.
19. Sawyers C (2004) Targeted Cancer Therapy. Nature 432: 294-297.
20. Liu L, Gerson SL (2006) Targeted modulation of MGMT: clinical implications. Clin Cancer Res 12: 328-331.
21. Kaina B, Ochs K, Grosch S, Fritz G, Lips J, et al. (2001) BER, MGMT, and MMR in defense against alkylation-induced genotoxicity and apoptosis. Prog. Nucleic Acid Res Mol Biol 68: 41-54.
22. Liu L, Taverna P, Hitacre CM, Chatterjee S, Gerson SL (1999) Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and - proficient colon cancer cells to methylating agents. Clin Cancer Res 5: 2908-2917.
23. Trivedi RN, Almeida KH, Fornsaglio JL, Schamus S, Sobol RW (2005) The role of base excision repair in the sensitivity and resistance to temozolomidemediated cell death. Cancer Res 65: 6394-400.
24. Trivedi RN, Wang XH, Jelezcova E, Goellner EM, Tang JB, et al. (2008) Human methyl purine DNA glycosylase and DNA polymerase beta expression collectively predict sensitivity to temozolomide. Mol Pharmacol 74: 505-516.
25. Karran P, Bignami M (1994) DNA damage tolerance, mismatch repair and genome instability. Bioessays 16: 833-839.
26. Liu L, Markowitz S, Gerson SL (1996) Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2- chloroethyl)nitrosourea. Cancer Res 56: 5375-5379.
27. Branch P, Aquilina G, Bignami M, Karran P (1993) Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature 362: 652-654.
28. Kawate H, Sakumi K, Tsuzuki T, Nakatsuru Y, Ishikawa T, et al. (1998) Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes. Proc Natl Acad Sci USA 95: 5116-5120.
29. Tentori L, Lacal PM, Benincasa E, Franco D, Faraoni I, et al. (1998) Role of wild-type p53 on the antineoplastic activity of temozolomide alone or combined with inhibitors of poly(ADP-ribose) polymerase. J Pharmacol Exp Ther 285: 884-893.
30. Fishel ML, He Y, Smith ML, Kelley MR (2007) Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. Cancer Ther Preclin 3: 260-267.
31. Liu L, Gerson SL (2004) Therapeutic impact of methoxyamine: blocking repair of abasic sites in the base excision repair pathway. Curr Opin Investig Drugs 5: 623-627.
32. Sobol RW, Wilson SH (2001) Mammalian DNA beta-polymerase in base excision repair of alkylation damage. Prog Nucleic Acid Res Mol Biol 68: 57-74.
33. Liu L, Nakatsuru Y, Gerson SL (2002) Base excision repair as a therapeutic target in colon cancer. Clin Cancer Res 8: 2985-2991.
34. Horton JK, Wilson SH (2007) Hypersensitivity phenotypes associated with genetic and synthetic inhibitor-induced base excision repair deficiency. DNA Repair (Amst) 6: 530-543.
35. Adhikari S, Choudhury S, Mitra PS, Dubash JJ, Sajankila SP, et al. (2008) Targeting base excision repair for chemosensitization. Anticancer Agents Med Chem 8: 351-357.
36. Jaiswal AS, Banerjee S, Panda H, Bulkin CD, Izumi T, et al. (2009) A novel inhibitor of DNA polymerase beta enhances the ability of temozolomide to impair the growth of colon cancer cells. Mol Cancer Res 7: 1973-1983.
37. Bei R, Marzocchella L, Turriziani M (2010) The use of temozolomide for the treatment of malignant tumors: clinical evidence and molecular mechanisms of action. Recent Pat. Anticancer Drug Discov 5: 172-187.
38. Hainsworth JD, Ervin T, Friedman E, Priego V, Murphy PB, et al. (2010) Concurrent radiotherapy and temozolomide followed by temozolomide and sorafenib in the first-line treatment of patients with glioblastoma multiforme. Cancer 116: 3663-3669.
39. Spiro TP, Liu L, Majka S, Haaga J, Willson JK, et al. (2001) Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase. Clin Cancer Res 7: 2309-2317.
40. Khan OA, Ranson M, Michael M, Olver I, Levitt NC, et al. (2008) Mortimer P, Watson AJ, Margison GP, Midgley R, Middleton MR. A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. Br J Cancer 98: 1614-1618.
41. Barcellos GB, Pauli I, Caceres RA, Timmers LF, Dias R, et al. (2008) Molecular modeling as a tool for drug discovery. Curr Drug Targets 9: 1084-1091.
42. Veselovsky AV, Ivanov AS (2003) Strategy of computer-aided drug design. Curr Drug Targets Infect Disord 3: 33-40.
43. Kroemer RT (2007) Structure-based drug design: docking and scoring. Curr Protein Pept Sci 8: 312-328.
44. Dhaliwal B, Chen YW (2009) Computational resources for protein modelling and drug discovery applications. Infect Disord Drug Targets 9: 557-562.
45. Narayan S, Jaiswal AS, Balusu R (2005) Tumor suppressor APC blocks DNA polymerase beta-dependent strand displacement synthesis during long patch but not short patch base excision repair and increases sensitivity to methylmethane sulfonate. J Biol Chem 280: 6942-6949.
46. Balusu R, Jaiswal AS, Armas ML, Bloom LB, Narayan S (2007) Structure/ function analysis of the interaction of adenomatous polyposis coli (APC) with DNA polymerase b and its implications for base excision repair. Biochemistry 46: 13961-13974.
47. De Azevedo WF, Jr. (2010) MolDock applied to structure-based virtual screening. Curr Drug Targets 11: 327-334.
48. Sawaya MR, Prasad R, Wilson SH, Kraut J, Pelletier H (1997) Crystal structures of human DNA polymerase beta complexed with gapped and nicked DNA: evidence for an induced fit mechanism. Biochemistry 36: 11205-11215.
49. Wallace AC, Laskowski RA, Thornton JM (1996) LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng 8: 127-134.
50. Prasad R, Dianov GL, Bohr VA, Wilson SH (2000) FEN1 stimulation of DNA polymerase beta mediates an excision step in mammalian long patch base excision repair. J Biol Chem 275: 4460-4466.
51. Liu Y, Beard WA, Shock DD, Prasad R, Hou EW, et al. (2005) DNA polymerase beta and flap endonuclease 1 enzymatic specificities sustain DNA synthesis for long patch base excision repair. J Biol Chem 280: 3665-3674.
52. Jaiswal AS, Balusu R, Armas ML, Kundu CN, Narayan S (2006) Mechanism of adenomatous polyposis coli (APC)-mediated blockage of long-patch base excision repair. Biochemistry 45: 15903-15914.
53. Kundu CN, Balusu R, Jaiswal AS, Gairola CG, Narayan S (2007) Cigarette smoke condensate-induced levels of adenomatous polyposis coli (APC) block long-patch base excision repair in breast epithelial cells. Oncogene 26: 1428-1438.
54. Kundu CN, Balusu R, Jaiswal AS, Narayan S (2007) Adenomatous polyposis coli-mediated hypersensitivity of mouse embryonic fibroblast cell lines to methylmethane sulfonate treatment: implication of base excision repair pathways. Carcinogenesis 28: 2089-2095.
55. Taverna P, Liu L, Hanson AJ, Monks A, Gerson SL (2000) Characterization of MLH1 and MSH2 DNA mismatch repair proteins in cell lines of the NCI anticancer drug screen. Cancer Chemother Pharmacol 46: 507-516.
56. Papadopoulos N, Nicolaides NC, Wei YF, Ruben SM, Carter KC, et al. (1994) Mutation of a mutL homolog in hereditary colon cancer. Science 263: 1625-1629.
57. Jacob S, Aguado M, Fallik D, Praz F (2001) The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Res 61: 6555-6562.
58. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, et al. (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308-4312.
59. Liu L, Taverna P, Hitacre CM, Chatterjee S, Gerson SL (1999) Pharmacologic disruption of base excision repair sensitizes mismatch repair-deficient and - proficient colon cancer cells to methylating agents. Clin Cancer Res 5: 2908-2917.
60. Jemal A, Siegel R, Ward E, Hao Y, Xu J, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 4: 225-249.
61. Newlands ES, Blackledge GR, Slack JA, Rustin GJ, Smith DB, et al. (1992) Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856). Br J Cancer 65: 287-291.
62. Brandes AA, Ermani M, Basso U, Paris MK, Lumachi F, et al. (2002) Temozolomide in patients with glioblastoma at second relapse after first line nitrosourea-procarbazine failure: a phase II study. Oncology 63: 38-41.
63. Seiter K, Liu D, Loughran T, Siddiqui A, Baskind P, et al. (2002) Phase I study of temozolomide in relapsed/refractory acute leukemia. J Clin Oncol 20: 3249-3253.
64. Trudeau ME, Crump M, Charpentier D, Yelle L, Bordeleau L, et al. (2010) Temozolomide in metastatic breast cancer (MBC): a phase II trial of the National Cancer Institute of Canada - Clinical Trials Group (NCIC-CTG). Ann Oncol 17: 952-956.
65. Cai W, Maldonado NV, Cui W, Harutyunyan N, Ji L, et al. (2010) Activity of irinotecan and temozolomide in the presence of O6-methylguanine-DNA methyltransferase inhibition in neuroblastoma pre-clinical models Br J Cancer 103: 1369-1379.
66. Kaina B, Christmann M, Naumann S, Roos WP (2007) MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents. DNA Repair (Amst) 6: 1079-1099.
67. Taverna P, Liu L, Hwang HS, Hanson AJ, Kinsella TJ, et al. (2001) Methoxyamine potentiates DNA single strand breaks and double strand breaks induced by temozolomide in colon cancer cells. Mutat Res 485: 269-281.
68. Sarkaria JN, Kitange GJ, James CD, Plummer R, Calvert H, et al. (2008) Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14: 2900-2908.
69. Koi M, Umar A, Chauhan DP, Cherian SP, Carethers JM, et al. (1994) Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation. Cancer Res 54: 4308-4312.